LIXTE collaborates with Roche and NKI on trial combining LB-100 with atezolizumab in MSI Low colon cancer

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Trial (NCT06012734) will test LB-100 plus Roche's PD-L1 inhibitor atezolizumab in immunotherapy-unresponsive MSI Low metastatic colon cancer.
LIXTE provides LB-100; Roche provides atezolizumab via imCORE Network; NKI is principal investigator.
About 85% of colon cancers are MSI Low; LB-100 may sensitize these tumors to immunotherapy, expanding treatment options.
This is second recent pharma-backed trial combining LB-100 with immunotherapy; GSK is funding a separate trial in clear cell ovarian cancer.
New pre-clinical data in EMBO Reports showed LB-100 can turn immunologically 'cold' tumors 'hot'.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.